- Abstract
- Core Tip
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (150)
- Timeline of Article Publication (0)
- Authors Evaluation (1)
- Article Quality Tracking (0)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2204)
All Articles published online
|
Publishing Process of This Article
|
Jan 21, 2025 (publication date) through Aug 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cheng CH, Hao WR, Cheng TH. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World J Gastroenterol 2025; 31(3): 98783 [PMID: 39839906 DOI: 10.3748/wjg.v31.i3.98783] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v31/i3/98783.htm |
| Number | Citing Articles |
| 1 |
Rong Hu, Dan Liu, Xiaofei Sun, Zhong Yu. New drugs approved by European medicines agency during 2024. European Journal of Medicinal Chemistry 2025; 294: 117761 doi: 10.1016/j.ejmech.2025.117761
|
| 2 |
Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao. MetALD: new insights and unraveling therapeutic potential. Metabolism and Target Organ Damage 2025; 5(3) doi: 10.20517/mtod.2025.65
|
| 3 |
Pascal Pellegrini, Thomas Gelbrich, Marijan Stefinovic, Sven Nerdinger, Doris E. Braun. From Structure to Stability: Exploring the Solid-State Forms of a Novel First-In-Class PPAR Agonist (Elafibranor). Crystal Growth & Design 2025; doi: 10.1021/acs.cgd.5c00844
|